Boost for AZ as Ultomiris gets CHMP nod for expanded label
pharmaphorum
JULY 26, 2021
Fresh from its takeover of Alexion, AstraZeneca has picked up a recommendation in the EU for an expansion of the label of Ultomiris, one of the main assets behind the $39 billion merger. The decision puts Ultomiris on course to be the first treatment for children with PNH in Europe, setting up a full EMA approval in the coming weeks.
52 
Let's personalize your content